Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Priti Jhingran"'
Autor:
Jane Loftus, Jen Wogen, David Oliveri, Darrin Benjumea, Priti Jhingran, Yong Chen, Jose Alvir, Elena Rivero-Sanz, Jack C. Kowalik, Michael P. Wajnrajch
Publikováno v:
Frontiers in Endocrinology, Vol 13 (2022)
BackgroundChildren with growth hormone deficiency (GHD) are treated with daily somatropin injections; however, poor treatment persistence and adherence have been recognized previously and have been shown to negatively impact growth outcomes. A recent
Externí odkaz:
https://doaj.org/article/b0c33c2a28494ac79452fab4bd05851c
Autor:
Jane Loftus, Bradley S. Miller, Craig S. Parzynski, Jose Alvir, Yong Chen, Priti Jhingran, Anu Gupta, Mitch DeKoven, Victoria Divino, Jenny Tse, Jing He, Michael Wajnrajch
Publikováno v:
Endocrine Practice. 28:565-571
Recombinant human growth hormone (somatropin) is recommended for children with growth hormone deficiency (GHD) to normalize adult height. Prior research has indicated an association between adherence to somatropin and height velocity. Further researc
Autor:
Ahmad Masri, Yong Chen, A. Carmine Colavecchia, Jose Alvir, Darrin Benjumea, Aaron Crowley, Priti Jhingran, Matthew Kent, Jen Wogen, Rahul Bhambri
Publikováno v:
Journal of Cardiac Failure. 29:690
Autor:
Jane Loftus, Jen Wogen, David Oliveri, Darrin Benjumea, Priti Jhingran, Yong Chen, Jose Alvir, Elena Rivero Sanz, Jack Charles Kowalik
Publikováno v:
Journal of the Endocrine Society. 6:A605-A606
Background Suboptimal adherence to, and persistence with, daily somatropin therapy to treat children with growth hormone deficiency (GHD) has been documented previously, and has also been shown to have negative effects on the growth response. Objecti
Autor:
Jane Loftus, Yong Chen, Anu Gupta, Michael P. Wajnrajch, Jose Ma. J. Alvir, Lawrence A. Silverman, Priti Jhingran, Mahesh Kumar, Sapna Prasad
Publikováno v:
Current medical research and opinion. 38(6)
The objective of this retrospective cohort study was to describe the adherence and discontinuation patterns of somatropin over 3 years among children with pGHD insured by Medicaid across the United States.Eligible children were aged ≥3 and16 years
Autor:
Ahmad Masri, Yong Chen, A. Carmine Colavecchia, Jose Maria Jimenez Alvir, Darrin Benjumea, Aaron Crowley, Priti Jhingran, Matthew Kent, Jenifer Wogen, Cindi Sounthonevat, Rahul Bhambri
Publikováno v:
Journal of the American College of Cardiology. 80:B175
Autor:
Mary Anne Dooley, Daniel J. Wallace, Vibeke Strand, Mark Kosinski, Rachel A. Mikolaitis, Graciela S. Alarcón, Ann E. Clarke, Greg Dennis, Ann L. Parke, Cindy Garris, Meenakshi Jolly, Priti Jhingran
Publikováno v:
Arthritis Care & Research. 66:1542-1550
Objective To derive and validate a brief patient-completed instrument, the Lupus Impact Tracker (LIT), to assess and monitor the impact of systemic lupus erythematosus (SLE). Methods Items for the LIT were selected from the LupusPRO, a validated pati
Autor:
Michael Schatz, Priti Jhingran, Theresa W. Guilbert, Kenneth J. Tomaszewski, Machaon Bonafede, Rebecca M. Hahn, Tiffany Bonus, Cindy Garris
Publikováno v:
Journal of Asthma. 48:126-132
Relationships of asthma control to other asthma outcomes have been incompletely documented.This study examined the relationship between asthma control and health-related quality of life (HRQL) and subsequent healthcare resource utilization.A 1-year o
Autor:
Christine A. Sorkness, T.B. Pendergraft, John J. Murray, Mark Kosinski, Michael Schatz, Philip Marcus, James T.C. Li, Robert A. Nathan, Priti Jhingran
Publikováno v:
Journal of Allergy and Clinical Immunology. 117:549-556
The development of the Asthma Control Test (ACT), a short, simple, patient-based tool for identifying patients with poorly controlled asthma, was recently described in patients under the routine care of an asthma specialist.We sought to evaluate the
Autor:
Antonio P. Legorreta, Priti Jhingran, Ranjani Manjunath, Amanda Gilmore, Richard D. O'Connor, Richard H. Stanford
Publikováno v:
Current Medical Research and Opinion. 22:453-461
Clinical trials have demonstrated improved efficacy of fluticasone propionate/salmeterol (100/50 mcg) in a single device (FSC) compared with montelukast (10 mg) (MON). This study was designed to assess asthma control, asthma-related quality of life,